Is age a prognostic factor for treatment outcome in renal cell cancer—A comprehensive review

Ramos-Barcelo, Enrique; Rioja, Jorge; Pes, Pilar Laguna; Rosette, Jean J.M.C.H. de la; Reijke, Theo M. de

doi:10.1016/j.critrevonc.2009.02.005

Cited by 3 publications

(2 citation statements)

References 53 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About half of the new diagnoses of renal cell carcinoma are reported in patients over 65 years of age, particularly in 25% of cases between 65 and 74 years and in another 25% of cases over 75 years [ 2 – 3 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy

Vitale¹,

Scagliarini²,

Galli³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

BackgroundResults from phase III clinical trial CheckMate 025 have established nivolumab as the standard of care for treatment of metastatic renal-cell carcinoma (mRCC) after VEGF inhibitor failure; however, elderly patients are under-represented in the registration trial and little is known about the activity of nivolumab in this subgroup. The purpose of the Expanded Access Program was to provide nivolumab to patients with mRCC who had progressed despite treatment with other agents that were considered standard of care.MethodsNivolumab 3 mg/kg was administered intravenously every 2 weeks to a maximum of 24 months or until progression or unacceptable toxicity. The current analysis included all patients from the EAP Italian cohort who had received ≥1 dose of nivolumab. Adverse events (AEs) were monitored using Common Terminology Criteria for Adverse Events v4.0.ResultsA total of 389 patients with advanced RCC were enrolled in the Italian cohort of the EAP and treated with nivolumab. Of these patients, 125 (32%) were at least 70 years of age and 70 (18%) were at least 75 years of age. Efficacy with nivolumab in the elderly patients was similar to that observed in the overall EAP population and in the CheckMate 025 trial. Safety was comparable between the elderly patients and the overall EAP population, and was consistent with what previously reported.ConclusionThe final results suggest that elderly patients with pretreated metastatic RCC may benefit from therapy with nivolumab.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy

Vitale¹,

Scagliarini²,

Galli³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Elderly patients are also another category garnering a particular interest as half of the newly diagnosed renal cell carcinoma are found in patients > 65 years of age, predominantly 25% cases between 65 and 74, and another 25% cases in > 75 years old [ 49 , 50 ]. There is a lack of significant data concerning the outcome of combination therapies in this population.…”

Section: Combination Therapy Versus Tki Alone In Selected Patient Subgroupsmentioning

confidence: 99%

Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?

et al. 2021

View full text Add to dashboard Cite

Purpose of Review Therapeutic alternatives to treat metastatic renal cell carcinoma (mRCC) are increasing, and combination therapies, including antiangiogenic agents and tyrosine kinase/mTOR/immune checkpoint inhibitors, are identified as the gold standard driven by the results of recent clinical studies. Nevertheless, the real-world RCC population is very heterogeneous, with categories of patients not represented in the enrolled trial population who may not benefit more from these treatments. The purpose of this expert review is to assess the rationale on which tyrosine kinase alone may still be a viable first-line treatment option for some subgroups of patients with mRCC. Recent Findings The first-line treatment with tyrosine kinase inhibitor monotherapy can still be considered an effective tool for addressing selected mRCCs, as highlighted by the successful outcome in a range of subjects such as favorable-risk patients, the ones suffering from autoimmune diseases, those with pancreatic or lung metastases, or previously undergoing organ transplantation and elderly subjects. Summary Some selected categories of patients may still benefit from monotherapy with TKI, and smart sequential therapies can also be considered instead of a combination strategy. Tyrosine kinase inhibitors can also act as immune modulator agents, boosting the immune response to facilitate and potentiate the therapeutic effectiveness of subsequent immunotherapy.

show abstract

Weighted Voting Analysis of DNA Microarray for Gene Selection and Gene Expression Analysis of Two Types of Rats Treated with Aristolochic Acid and Ochratoxin A Drugs

Masoum¹,

Ebrahimabadi²

2014

OALib

View full text Add to dashboard Cite

Is age a prognostic factor for treatment outcome in renal cell cancer—A comprehensive review

Cited by 3 publications

References 53 publications

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy

Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?

Weighted Voting Analysis of DNA Microarray for Gene Selection and Gene Expression Analysis of Two Types of Rats Treated with Aristolochic Acid and Ochratoxin A Drugs

Contact Info

Product

Resources

About